Author

E. Makdasi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:mouse· 6 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:multiome· 1

Frequent Co-Authors

R. Alcalay· 7 shared R. Rosenfeld· 7 shared D. Gur· 6 shared M. Aftalion· 6 shared O. Mazor· 6 shared E. Epstein· 5 shared S. Yitzhaki· 5 shared T. Chitlaru· 5 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

R. Alcalay

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies

T. Noy-Porat, A. Edri, R. Alcalay, E. Makdasi, D. Gur, M. Aftalion, Y. Evgy, A. Beth-Din, Y. Levy, E. Epstein, O. Radinsky, A. Zauberman, S. Lazar, S. Yitzhaki, H. Marcus, , O. Mazor

This study shows that Fc-independent monoclonal antibodies can neutralize SARS-CoV-2 in mice, reducing viral load and preventing mortality without Fc-dependent effector functions.

bioRxiv · May 15, 2021Immunology

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants

E. Makdasi, A. Zvi, R. Alcalay, T. Noy-Porat, E. Peretz, A. Mechaly, Y. Levy, E. Epstein, T. Chitlaru, A. Tennenhouse, M. Aftalion, D. Gur, N. Paran, H. Tamir, O. Zimhony, , R. Rosenfeld

This study evaluates the neutralization potency of four SARS-CoV-2 mAbs against spike mutations and two variants of concern, finding that MD65 and BL6 retain effectiveness against B.1.1.7 and B.1.351.

bioRxiv · Apr 1, 2021Immunology

A lipid nanoparticle RBD-hFc mRNA vaccine protects hACE2 transgenic mice against lethal SARS-CoV-2 infection

U. Elia, S. Rotem, E. Bar-Haim, S. Ramishetti, G. S. Naidu, D. Gur, M. Aftalion, M. Israeli, A. Bercovich-Kinori, R. Alcalay, E. Makdasi, T. Chitlaru, R. Rosenfeld, T. Israely, S. Melamed, , O. Cohen

This study evaluates an mRNA vaccine against SARS-CoV-2 in hACE2 transgenic mice, showing 70% protection against a lethal infection.

bioRxiv · Mar 29, 2021Microbiology

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice

T. Noy-Porat, A. Mechaly, Y. Levy, E. Makdasi, R. Alcalay, D. Gur, M. Aftalion, R. Falach, S. Leviatan Ben-Arye, S. Lazar, A. Zauberman, E. Epstein, T. Chitlaru, S. Weiss, H. Achdout, , R. Rosenfeld

This study identifies and characterizes neutralizing antibodies targeting the SARS-CoV-2 spike N-terminal domain, showing their protective efficacy in mice.

bioRxiv · Feb 2, 2021Immunology

Mice with Induced Pulmonary Comorbidities Display Severe Lung Inflammation and Mortality following Exposure to SARS-CoV-2

R. Falach, L. Bar-On, S. Lazar, T. Kadar, O. Mazor, M. Aftalion, D. Gur, O. Shifman, O. Israeli, I. Cohen-Gihon, G. Zaide, H. Gutman, Y. Evgy, Y. Vagima, E. Makdasi, , T. Sabo

This study shows that CD-1 mice with induced pulmonary comorbidities develop severe lung inflammation and high mortality after SARS-CoV-2 infection.

bioRxiv · Oct 28, 2020 · PreprintPathology

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

R. Rosenfeld, T. Noy-Porat, A. Mechaly, E. Makdasi, Y. Levy, R. Alcalay, R. Falach, M. Aftalion, E. Epstein, D. Gur, T. Chitlaru, E. B. Vitner, S. Melamed, B. Politi, A. Zauberman, , O. Mazor

This study shows that the human monoclonal antibody MD65 can rescue 100% of SARS-CoV-2 infected mice when administered up to 3 days post-exposure.

bioRxiv · Oct 26, 2020Immunology

Design of SARS-CoV-2 RBD mRNA Vaccine Using Novel Ionizable Lipids

U. Elia, R. Srinivas, N. Dammes, E. Bar-Haim, G. S. Naidu, E. Makdasi, O. Cohen, D. Peer

This study designs an mRNA vaccine targeting SARS-CoV-2 RBD using novel ionizable lipids, showing strong immune responses in mice.

bioRxiv · Oct 15, 2020Immunology

Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

T. Noy-Porat, E. Makdasi, R. Alcalay, A. Mechaly, Y. Levy, A. Bercovich-Kinori, A. Zauberman, H. Tamir, Y. Yahalom-Ronen, M. Israeli, E. Epstein, H. Achdout, S. Melamed, T. Chitlaru, S. Weiss, , R. Rosenfeld

This paper isolates and characterizes a panel of human neutralizing monoclonal antibodies targeting SARS-CoV-2 spike at multiple epitopes, suggesting their potential for combined post-exposure therapy.

bioRxiv · May 20, 2020Immunology